Ross Moat
Förmögenhet: 581 963 $ per 2026-05-31
Förmögenhet: 581 963 $ per 2026-05-31
Ross Moat currently works at Kiniksa Pharmaceuticals Ltd. as Chief Commercial Officer & Senior Vice President since 2022.
Mr. Moat also works at Kiniksa Pharmaceuticals International Plc as Chief Operating Officer & Executive Vice President starting in 2026.
Former roles include General Manager at Synageva BioPharma Corp.
and VP-EMEA Marketing & Commercial Operations at Novartis Gene Therapies, Inc. from 2018 to 2019.
Education includes an undergraduate degree from Middlesex University.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
0,03 % | 2026-04-09 | 12 029 ( 0,03 % ) | 581 963 $ | 2026-05-31 |
| Företag | Position | Start |
|---|---|---|
Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops and delivers therapeutic medicines for patients suffering from cardiovascular diseases | Företagsledare/Principal | 2021-02-01 |
| Företag | Position | Slut |
|---|---|---|
| AVEXIS INC | Försäljning & Marknadsföring | 2019-06-01 |
| SYNAGEVA BIOPHARMA CORP | Företagsledare/Principal | - |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 4 |
|---|---|
Middlesex University
Middlesex University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Synageva BioPharma Corp.
Synageva BioPharma Corp. BiotechnologyHealth Technology Develops and manufactures biopharmaceutical products | Health Technology |
Novartis Gene Therapies, Inc.
Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Operates as a clinical-stage gene therapy company | Health Technology |
Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops and delivers therapeutic medicines for patients suffering from cardiovascular diseases | Health Technology |
Välj din utgåva
All finansiell information anpassad till den nationella nivån